BioMarin Pharmaceutical (BMRN) Earnings Date, Estimates & Call Transcripts $68.21 -0.52 (-0.76%) As of 02:30 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends BioMarin Pharmaceutical Latest Earnings SummaryUpcoming Q1 Earnings DateApr. 23After Market ClosesEstimatedActual EPS (Feb. 19) $0.72 Beat By $0.18 Consensus EPS (Feb. 19) $0.54 BioMarin Pharmaceutical issued Q4 2024 earnings on February 19, 2025, reporting an EPS of $0.72, which topped analysts' consensus estimates of $0.54 by $0.18. Quarterly revenue was reported to be $747.31 million, above analyst estimates of $711.05 million. With a trailing EPS of $2.20 and a P/E Ratio of 31.00, BioMarin Pharmaceutical's earnings are expected to grow 38.41% next year, from $3.15 to $4.36 per share. Conference CallConference Call TranscriptEarnings Press ReleaseEarnings Slide DeckPowered by BMRN Upcoming EarningsBioMarin Pharmaceutical's next earnings date is estimated for Wednesday, April 23, 2025, based off prior year's reporting schedules. Get BioMarin Pharmaceutical Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BioMarin Pharmaceutical and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataBMRN Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.BMRN Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. BioMarin Pharmaceutical Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateCompany GuidanceQ1 20253$0.48$0.68$0.59 Q2 20253$0.69$0.81$0.74 Q3 20253$0.73$0.83$0.79 Q4 20253$0.67$0.82$0.72 FY 202512$2.57$3.14$2.85 Q1 20261$0.78$0.78$0.78 Q2 20261$0.86$0.86$0.86 Q3 20261$0.91$0.91$0.91 Q4 20261$0.97$0.97$0.97 FY 20264$3.52$3.52 $3.52 BioMarin Pharmaceutical Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails 4/23/2025(Estimated)-------2/19/2025Q4 2024$0.54$0.72+$0.18$0.64$711.05M$747.31M10/29/2024Q3 2024$0.78$0.55 -$0.23$0.93$703.37M$746.00M8/5/2024Q2 2024$0.38$0.77+$0.39$0.99$660.51M$712.03M4/24/2024Q1 2024$0.37$0.49+$0.12$0.52$649.75M$648.83M2/22/2024Q4 2023$0.4450$0.49+$0.0450$0.41$639.53M$646.21M11/1/2023Q3 2023$0.28$0.26 -$0.02$0.31$603.51M$581.33M7/31/2023Q2 2023$0.24$0.34+$0.10$0.39$591.46M$595.28M4/26/2023Q1 2023$0.24$0.39+$0.15$0.51$572.53M$596.42M2/27/2023Q4 2022$0.12$0.11 -$0.01$0.22$533.88M$537.54M BioMarin Pharmaceutical Earnings - Frequently Asked Questions When is BioMarin Pharmaceutical's earnings date? BioMarin Pharmaceutical has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, April 23rd, 2025 based off last year's report dates. Learn more on BMRN's earnings history. What guidance has BioMarin Pharmaceutical issued on next quarter's earnings? BioMarin Pharmaceutical updated its FY 2025 earnings guidance on Wednesday, February, 19th. The company provided earnings per share guidance of 4.200-4.400 for the period, compared to the consensus earnings per share estimate of 4.160. The company issued revenue guidance of $3.1 billion-$3.2 billion, compared to the consensus revenue estimate of $3.1 billion. Did BioMarin Pharmaceutical beat their earnings estimates last quarter? In the previous quarter, BioMarin Pharmaceutical (NASDAQ:BMRN) reported $0.72 earnings per share (EPS) to beat the analysts' consensus estimate of $0.54 by $0.18. Learn more on analysts' earnings estimate vs. BMRN's actual earnings. How can I listen to BioMarin Pharmaceutical's earnings conference call? The conference call for BioMarin Pharmaceutical's latest earnings report can be listened to online. Listen to Conference Call How can I read BioMarin Pharmaceutical's conference call transcript? The conference call transcript for BioMarin Pharmaceutical's latest earnings report can be read online. Read Transcript How much revenue does BioMarin Pharmaceutical generate each year? BioMarin Pharmaceutical (NASDAQ:BMRN) has a recorded annual revenue of $2.85 billion. How much profit does BioMarin Pharmaceutical generate each year? BioMarin Pharmaceutical (NASDAQ:BMRN) has a recorded net income of $167.65 million. BMRN has generated $2.20 earnings per share over the last four quarters. What is BioMarin Pharmaceutical's price-to-earnings ratio? BioMarin Pharmaceutical (NASDAQ:BMRN) has a trailing price-to-earnings ratio of 31.00 and a forward price-to-earnings ratio of 21.65. The price/earnings-to-growth ratio is 0.58. What is BioMarin Pharmaceutical's EPS forecast for next year? BioMarin Pharmaceutical's earnings are expected to grow from $3.15 per share to $4.36 per share in the next year, which is a 38.41% increase. More Earnings Resources from MarketBeat Related Companies ALNY Earnings Date BIIB Earnings Date UTHR Earnings Date INCY Earnings Date NBIX Earnings Date EXEL Earnings Date EXAS Earnings Date RGEN Earnings Date HALO Earnings Date MDGL Earnings Date Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Hims & Hers Earnings Could Be a Game Changer—What to Do NowAnalysts See Buying Opportunity in NVIDIA Before EarningsAirbnb's Earnings: Sky High Results, Grounded Guidance?Is Coinbase Stock a Buy After Earnings?CVS Health: Earnings Beat Ignites Stock RallyQualcomm’s Post-Earnings Dip: A Prime Buying Opportunity?Cirrus Logic Upgraded After Q3 Earnings Beat—More Gains Ahead? This page (NASDAQ:BMRN) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredTop Picks for Trump’s Pro-Crypto America10,000% Crypto Opportunities in 2025 27 of the brightest minds in crypto share exclusive intel… Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioMarin Pharmaceutical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioMarin Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
